Cantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE